Oseltamivir resistance during treatment of H7N9 infection

@article{Hay2013OseltamivirRD,
  title={Oseltamivir resistance during treatment of H7N9 infection},
  author={Alan J. Hay and Frederick G. Hayden},
  journal={The Lancet},
  year={2013},
  volume={381},
  pages={2230-2232}
}

Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses

It is demonstrated that R292K, E119V, and I222K reduced the inhibitory activity of oseltamivir, not only in the NI assay, but also in infected ferrets, judged particularly by viral loads in nasal washes, and may signal the need for alternative therapeutics.

A review of neuraminidase inhibitor susceptibility in influenza strains

Although in 2014, the majority of circulating human influenza viruses remains susceptible to all NAIs, the emergence of oseltamivir-resistant influenza variants that could retain viral transmissibility, highlights the necessity for enhanced epidemiological and microbiological surveillance and clinical assessment of antiviral resistance.

Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil

In mice, oral administration of BXM was completely protected from a lethal A/Anhui/1/2013 (H7N9) challenge, and reduced virus titers more than 2–3 log in the lungs, and the potent therapeutic effects of BXA in mice were still observed when a higher virus dose was administered or treatment was delayed up to 48 hours post infection.

Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment

It is reported that Alferon N can inhibit wild type and 292K H7N9 viruses replication in vitro and this would allow a rapid regulatory approval process for this drug under pandemic threat.

Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model

The data show that repeated administration of peramivir at 30 mg/kg of body weight successfully eradicated the virus from the respiratory tract and extrapulmonary tissues during the acute response, prevented clinical signs of the disease, including neuropathy, and eventually protected mice against lethal H7N9 influenza virus infection.

Anti-H7N9 avian influenza A virus activity of interferon in pseudostratified human airway epithelium cell cultures

Both rhIFN-α2b and rhIFn-λ1 had antiviral activity against H7N9, and this protection was related to the induction of ISGs.

H7N9 avian influenza A virus in China: a short report on its circulation, drug resistant mutants and novel antiviral drugs

The H7N9 virus is a reassortant virus containing internal genes from the H9N2 virus and previously described mammalian adaption markers which could allow the virus to adapt efficiently to a mammalian host.

Effective strategy for managing H7N9 virus infection

The most effective approach to managing the problem of H7N9 virus infection is to educate the general public on those aspects of healthcare, such as self-prevention and promotion of basic sanitation, which relate to the transmission of respiratory infections.

H7N9 Influenza Virus in China.

This review summarizes the biological properties of the H7N9 viruses, specifically their genetic evolution, adaptation, pathogenesis, receptor binding, transmission, drug resistance, and antigenic variation, as well as the prevention and control measures.

References

SHOWING 1-10 OF 25 REFERENCES

Oseltamivir resistance during treatment of influenza A (H5N1) infection.

It is suggested that resistance can emerge during the currently recommended regimen of oseltamivir therapy and may be associated with clinical deterioration and that the strategy for the treatment of influenza A (H5N1) virus infection should include additional antiviral agents.

Determinants of antiviral effectiveness in influenza virus A subtype H5N1.

Oseltamivir is especially effective for treating H5N1 infection when given early and before onset of respiratory failure, and the effect of viral clade on fatality and treatment response deserves further investigation.

Poor responses to oseltamivir treatment in a patient with influenza A (H7N9) virus infection

This case calls for increased awareness of potential resistance of H7N9 to oseltamivir, which is the recommended choice of treatment, after a 56-year-old male patient was presented with fever and cough and swab specimens of this patient were still positive for H7n9.

Efficacy of Oseltamivir Therapy in Ferrets Inoculated with Different Clades of H5N1 Influenza Virus

Early oseltamivir treatment is crucial for protection against highly pathogenic H5N1 viruses and the higher dose may be needed for the treatment of more virulent viruses.

Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09.

  • J. LouieSamuel Yang T. Uyeki
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2012
NAI treatment of critically ill pH1N1 patients improves survival, while earlier treatment conveyed the most benefit, patients who started treatment up to 5 days after symptom onset also were more likely to survive.

Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.

The new H5N1 antigenic variant VN1203/04 was more pathogenic in mice than was A/HK/156/97 virus, and a prolonged and higher-dose oseltamivir regimen may be required for the most beneficial antiviral effect.

The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design

It may be possible to exploit the size and location of the group-1 cavity to develop new anti-influenza drugs, according to X-ray crystallography, which shows that these two groups of neuraminidases are structurally distinct.